Revefenacin Area Under the Curve Spirometry in Patients with Moderate to Very Severe COPD

Purpose: Several lung function endpoints are utilized in clinical trials of inhaled bronchodilators for chronic obstructive pulmonary disease (COPD). Trough forced expiratory volume in 1 second (FEV 1 ) is a commonly reported endpoint in COPD trials and can be complemented by area under the FEV 1 vs time curve (FEV 1 AUC), which provides information on duration and consistency of bronchodilation over a dosing interval. Revefenacin, a once-daily bronchodilator, significantly improved lung function in patients with COPD when measured by trough FEV 1 in two replicate Phase 3 trials. Here, we report an FEV 1 AUC substudy using data from these trials. Patients and Methods: This post hoc analysis examined substudy data from 12-week replicate Phase 3 trials (NCT02459080/NCT02512510); patients with moderate to very severe COPD were randomized 1:1 to revefenacin 175 μg or placebo once daily. The substudy patients had FEV 1 AUC 0– 2h assessed on Day 1, and those who continued to Day 84 also underwent 24-hour serial spirometry postdose where FEV 1 AUC 0– 2h, AUC 0– 12h , AUC 12-24h , and AUC 0– 24h were evaluated. Results: Fifty and 47 patients who received revefenacin and placebo underwent 24-hour serial spirometry; most baseline characteristics were aligned between groups. At Day 84 postdose, revefenacin demonstrated sustained improvements in bronchodilation over 24 hours; differences in least squares mean vs placebo were 282, 220, 205, and 212 mL for FEV 1 AUC 0– 2h , AUC 0– 12h , AUC 12– 24h , and AUC 0– 24h (all P < 0.001), respectively. Conclusion: This substudy analysis supplements previous findings that revefenacin provides sustained bronchodilation over 24 hours. Assessing additional complementary COPD clinical trial endpoints can help clinicians make treatment decisions.